Audentes Therapeutics (NASDAQ:BOLD) Lowered to Neutral at Guggenheim

Guggenheim lowered shares of Audentes Therapeutics (NASDAQ:BOLD) from a buy rating to a neutral rating in a research note published on Tuesday, Benzinga reports.

BOLD has been the topic of a number of other research reports. Chardan Capital reiterated a buy rating and set a $50.00 price objective on shares of Audentes Therapeutics in a research note on Sunday, October 6th. William Blair reissued a hold rating on shares of Audentes Therapeutics in a report on Wednesday, August 7th. Evercore ISI raised shares of Audentes Therapeutics from an in-line rating to an outperform rating in a research note on Wednesday, November 27th. Robert W. Baird initiated coverage on shares of Audentes Therapeutics in a report on Wednesday, October 2nd. They set an underperform rating and a $10.00 target price on the stock. Finally, ValuEngine lowered shares of Audentes Therapeutics from a buy rating to a hold rating in a research report on Friday, November 8th. One investment analyst has rated the stock with a sell rating, twelve have issued a hold rating and six have assigned a buy rating to the company. The company currently has an average rating of Hold and an average price target of $44.50.

NASDAQ:BOLD opened at $58.93 on Tuesday. Audentes Therapeutics has a 52-week low of $17.95 and a 52-week high of $59.01. The company has a market cap of $1.33 billion, a P/E ratio of -17.33 and a beta of 1.77. The stock’s 50-day simple moving average is $28.32 and its 200 day simple moving average is $33.21.

Audentes Therapeutics (NASDAQ:BOLD) last issued its quarterly earnings results on Thursday, November 7th. The biotechnology company reported ($1.00) EPS for the quarter, beating the consensus estimate of ($1.07) by $0.07. During the same period last year, the firm earned ($0.97) EPS. Research analysts anticipate that Audentes Therapeutics will post -4.13 EPS for the current year.

In related news, Director Louis G. Lange sold 10,000 shares of the company’s stock in a transaction dated Monday, September 23rd. The shares were sold at an average price of $32.16, for a total value of $321,600.00. Following the transaction, the director now owns 276,044 shares in the company, valued at approximately $8,877,575.04. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CEO Matthew R. Patterson sold 14,426 shares of the company’s stock in a transaction dated Friday, November 8th. The shares were sold at an average price of $30.00, for a total transaction of $432,780.00. Following the completion of the transaction, the chief executive officer now owns 127,820 shares in the company, valued at approximately $3,834,600. The disclosure for this sale can be found here. 5.30% of the stock is currently owned by insiders.

Several large investors have recently modified their holdings of the company. BlackRock Inc. grew its position in shares of Audentes Therapeutics by 14.2% in the second quarter. BlackRock Inc. now owns 3,333,445 shares of the biotechnology company’s stock valued at $126,204,000 after purchasing an additional 413,768 shares during the last quarter. Great Point Partners LLC increased its stake in shares of Audentes Therapeutics by 29.2% during the third quarter. Great Point Partners LLC now owns 2,485,000 shares of the biotechnology company’s stock worth $69,804,000 after purchasing an additional 562,063 shares during the period. Vanguard Group Inc. lifted its holdings in Audentes Therapeutics by 4.5% during the 2nd quarter. Vanguard Group Inc. now owns 1,971,206 shares of the biotechnology company’s stock worth $74,629,000 after purchasing an additional 84,659 shares during the last quarter. Victory Capital Management Inc. lifted its holdings in Audentes Therapeutics by 2.7% during the 2nd quarter. Victory Capital Management Inc. now owns 904,221 shares of the biotechnology company’s stock worth $34,233,000 after purchasing an additional 23,620 shares during the last quarter. Finally, Millennium Management LLC lifted its holdings in Audentes Therapeutics by 49.2% during the 3rd quarter. Millennium Management LLC now owns 773,279 shares of the biotechnology company’s stock worth $21,721,000 after purchasing an additional 255,086 shares during the last quarter. Institutional investors own 98.08% of the company’s stock.

Audentes Therapeutics Company Profile

Audentes Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases caused by single gene defects. The company is developing AT132, which is in Phase I/II clinical studies for the treatment of X-linked myotubular myopathy (XLMTM); AT342 that is in Phase I/II clinical studies to treat crigler-najjar syndrome; AT845, which is in preclinical studies for the treatment of pompe disease; and AT307 to treat CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia.

Read More: When is a capital gain realized?

Analyst Recommendations for Audentes Therapeutics (NASDAQ:BOLD)

Receive News & Ratings for Audentes Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.